Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib: pBoth EU and US regulatory advisors are currently assessing the drug/p

Commentaires

Articles les plus consultés